caps news

CAPS Opens Newest Facility in Lehigh Valley, PA

Sterile Compounding Pharmacy brings jobs to the Lehigh Valley

Bethlehem, PA – June 28, 2012 – B. Braun Medical Inc. (“B. Braun”) and Central Admixture Pharmacy Services, Inc. (“CAPS”) announced that Governor Tom Corbett will be represented by Secretary C. Alan Walker from the Pennsylvania Department of Community & Economic Development as the honored guest at a ribbon cutting ceremony for CAPS newest facility in Allentown. The ceremony to be held Thursday, June 28 at 11:30 a.m. will celebrate the opening of the first CAPS admixture pharmacy of its kind. The 32,000 square foot sterile compounding pharmacy in Allentown brings the latest in engineering and technology to support the reduction of medication errors that affect health care and joins the fast-growing twenty-five location nationwide network of CAPS facilities.

Although Governor Tom Corbett was unable to attend the ribbon cutting ceremony today, he did relay the following statement: “My administration is working every day to cultivate a business climate in Pennsylvania that enables companies like B. Braun and CAPS to grow and create jobs,” said Corbett. “Today’s announcement means that more than 70 Pennsylvanians will have the opportunity to secure a good-paying job.” 

According to B. Braun’s Senior Vice President and Chief Financial Officer, Bruce Heugel, the opening of CAPS new facility is an example of the “positive business environment that has been created in Pennsylvania and in the Lehigh Valley.” The CAPS facility will ultimately create seventy-three new jobs in the Lehigh Valley including opportunities for pharmacists and pharmacy technicians. Mr. Heugel, who is also a member of the Lehigh Valley Economic Development Corporation’s Board of Directors, said “CAPS considered several other locations but none as attractive as this community. Opening the CAPS facility in Allentown shows that the ‘regional approach’ to economic development is working to provide the opportunities that grow jobs in the community.”   

Since becoming part of the B. Braun group of companies as part of an acquisition of McGaw, Inc. in 1997, CAPS has grown from nine locations to its current network by constantly staying ahead of increasing standards that are required to compound sterile preparations. The new facility in Allentown will be the third CAPS facility in the State and it will enjoy a relationship of cooperation with the Lehigh Career and Technical Institute, Pennsylvania’s largest vocational school. Already one of the largest employers in the Lehigh Valley, B. Braun and CAPS see this relationship as a symbiotic partnership that ensures the highest quality and safety standards of the fast-growing and industry-leading company while providing career opportunities for its home-grown graduates.

About B. Braun

Since the early 19th Century, B. Braun has met a myriad of challenges in modern medical therapy with meaningful and trusted solutions. The B. Braun group of companies, including
B. Braun, Aesculap and CAPS, represent thousands of innovations in acute pain management and infusion therapy that are intended to improve care and lower costs while reducing risks to patients and workers. Guided by the company’s “Sharing Expertise®” philosophy, B. Braun works with motivated partners and customers to address the critical issues of infection prevention, medication safety and environmental responsibility.

The B. Braun corporate mission to bring solutions that lead to better patient care have earned the company dozens of awards, certifications and recognitions for innovative products, employment practices, “green” initiatives and community responsibility throughout the world.  Consistently recognized by Frost & Sullivan for its medical technology and support services,
B. Braun provides professional training through its Aesculap Academy, reaching over 45,000 healthcare professionals each year, teaching best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives. For more information, call 800-227-2862, e-mail us at or visit B. Braun at